Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jul 26;6:26. doi: 10.1186/s13395-016-0098-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 4 — Effects of cisplatin and CDD866 on time-to-progression. Time-to-progression expressed by percentage of event defined by interruption criteria (a); median days elapsed before reaching an interruption criterion (b), expressed by box and whiskers with min to max; ^&& P < 0.01 versus CT-26 control; ^## P < 0.01 versus CT-26 cisplatin. Distribution by termination criterion (c) and breakdown of time-to-progression by body weight loss (d) and tumor volume (e)